Histamine and Bradykinin Pharmacology

Bradykinin is generated when plasma kallikrein — itself activated from prekallikrein by factor XII (Hageman factor) upon contact with damaged endothelium or foreign surfaces — cleaves high-molecular-weight kininogen to release the bradykinin peptide. Once released, bradykinin has an extremely short plasma half-life of approximately 15 to 30 seconds. The principal enzyme responsible for its degradation is angiotensin converting enzyme, which is also called kininase II. Angiotensin converting enzyme cleaves two amino acids from the C-terminus of bradykinin, rendering it inactive. A second enzyme, kininase I (carboxypeptidase N), also contributes to bradykinin inactivation in plasma.

The dual role of angiotensin converting enzyme — converting angiotensin I to angiotensin II and simultaneously degrading bradykinin — is the pharmacological foundation of angiotensin converting enzyme inhibitor adverse effects. When angiotensin converting enzyme is inhibited by drugs such as lisinopril or enalapril, bradykinin accumulates in tissues that normally depend on angiotensin converting enzyme for its clearance.

The B2 receptor is constitutively expressed throughout the body and mediates the acute physiological and pathophysiological effects of bradykinin. It couples primarily to Gq, activating phospholipase C and raising intracellular calcium. In vascular endothelium, B2 activation stimulates nitric oxide synthase, producing nitric oxide that diffuses to vascular smooth muscle and causes vasodilation; simultaneously it increases vascular permeability by promoting gap formation between endothelial cells. In sensory neurons, B2 receptor activation produces pain and sensitizes nociceptors to other stimuli. In bronchial smooth muscle, it causes bronchoconstriction.

The B2 receptor is the primary target of icatibant, the drug used to treat acute hereditary angioedema attacks.

The B1 receptor is normally expressed at very low levels in most tissues but is dramatically upregulated in response to tissue injury and inflammation. Its primary endogenous agonist is des-Arg9-bradykinin, a metabolite produced when kininase I cleaves the C-terminal arginine from bradykinin — making this degradation step a generator of B1 receptor activity rather than simple inactivation. B1 receptor activation contributes primarily to chronic pain sensitization and sustained inflammatory responses at sites of prolonged tissue injury, as in arthritis and neuropathic pain states.

Angiotensin converting enzyme normally degrades bradykinin in the bronchial mucosa. When angiotensin converting enzyme is inhibited, bradykinin accumulates locally and sensitizes bronchial sensory C fibers via B2 receptor activation, producing the characteristic dry, nonproductive cough that begins within days to weeks of starting the drug. The cough is not dose-dependent — it reflects the patient's individual sensitivity to bradykinin accumulation — and resolves within days to weeks of discontinuing the angiotensin converting enzyme inhibitor. It is more common in individuals of East Asian ancestry than in those of European ancestry.

The management is straightforward: switch the patient to an angiotensin receptor blocker. Angiotensin receptor blockers block the angiotensin II receptor directly without inhibiting angiotensin converting enzyme, so bradykinin degradation remains intact and cough does not occur at increased rates.

Angiotensin converting enzyme inhibitor-induced angioedema is less common than cough but potentially life-threatening. Bradykinin accumulation in the dermal and submucosal microvasculature produces B2 receptor-mediated vasodilation and increased vascular permeability, causing tissue edema in the face, lips, tongue, pharynx, and larynx. Laryngeal involvement can compromise the airway and is a medical emergency. African American patients have a three- to fivefold higher risk of angiotensin converting enzyme inhibitor-induced angioedema than other groups, attributed to differences in bradykinin metabolism.

The critical clinical feature of angiotensin converting enzyme inhibitor angioedema is that it does not respond to epinephrine, H1 antihistamines, or corticosteroids — because histamine is not the mediator. These treatments address histamine-mediated angioedema and are ineffective when bradykinin is driving the reaction. Failure to respond to standard allergy treatments in a patient on an angiotensin converting enzyme inhibitor should immediately prompt recognition of bradykinin-mediated angioedema and escalation to airway management.

The management is to stop the angiotensin converting enzyme inhibitor permanently and switch to an angiotensin receptor blocker, which does not cause bradykinin accumulation. Patients who have experienced angiotensin converting enzyme inhibitor angioedema should never receive another angiotensin converting enzyme inhibitor.

Hereditary angioedema is the paradigm disorder of pathological bradykinin excess. In the most common forms (types I and II), patients have deficiency or dysfunction of C1 inhibitor, a protein that normally restrains plasma kallikrein activity. Without adequate C1 inhibitor, kallikrein is unregulated and continuously generates bradykinin from high-molecular-weight kininogen, causing episodic attacks of subcutaneous and submucosal edema.

Hereditary angioedema attacks affect the extremities, abdomen, face, and upper airway. Abdominal attacks cause severe pain, nausea, and vomiting that can mimic a surgical emergency. Laryngeal attacks are life-threatening. The attacks are not histamine-mediated — antihistamines and epinephrine are ineffective and should not be relied upon for treatment. This is the highest-yield distinguishing fact about hereditary angioedema at the Step 1 level.

Lanadelumab is a monoclonal antibody that binds and inhibits plasma kallikrein, preventing bradykinin generation at its source. Administered subcutaneously every two to four weeks, it significantly reduces the frequency of hereditary angioedema attacks and is the preferred long-term prophylactic agent for most patients.

Danazol, an attenuated androgen, was historically used for long-term prophylaxis before modern biologic agents became available. It works by upregulating hepatic C1 inhibitor gene expression, raising plasma C1 inhibitor levels toward normal. It remains an option in resource-limited settings but has been largely replaced by lanadelumab due to its dose-dependent adverse effects: virilization in women, hepatotoxicity with long-term use, and lipid abnormalities. Danazol is tested at Step 1 primarily in the context of its mechanism (upregulates C1 inhibitor synthesis) and its adverse effects.

Ecallantide is a plasma kallikrein inhibitor used for acute attacks, but it requires administration by a healthcare provider due to the risk of anaphylaxis. It is lower yield than icatibant at the Step 1 level; know that it targets kallikrein rather than the B2 receptor.

Histamine-mediated angioedema almost always occurs in the context of urticaria — the same mast cell degranulation that releases histamine into the vasculature also produces histamine-driven wheals in the skin. Bradykinin-mediated angioedema occurs without urticaria because mast cells are not involved. A patient with angioedema but no urticaria should immediately prompt consideration of a bradykinin mechanism, particularly if the patient is taking an angiotensin converting enzyme inhibitor or has a family history of episodic swelling.

If a patient with angioedema does not respond to intramuscular epinephrine and antihistamines, histamine-mediated angioedema is unlikely and a bradykinin mechanism should be urgently considered. This non-response is itself a diagnostic signal. Continuing to administer histamine-targeted treatments while the airway is compromising is a recognized cause of preventable death in hereditary angioedema and angiotensin converting enzyme inhibitor angioedema.